Wednesday, 17 July 2019

Suven secures product patents in China, Eurasia

31 August 2018 | News

The granted claims of the patents are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson's and schizophrenia.

Representative Image | Image Credit: Wikimedia Commons

Representative Image | Image Credit: Wikimedia Commons

Suven Life Sciences has said that it has been granted a product patent each by China and Eurasia corresponding to a new chemical entity (NCE) for the treatment of disorders associated with neurodegenerative diseases.

These patents are valid till 2034.

"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical needs with a huge market potential globally," Suven Life CEO Venkat Jasti said.

The granted claims of the patents are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson's and schizophrenia.

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls